EE333 Analysis of the Cost of Managing Patients with Advanced or Metastatic Non-Small Cell Lung Cancer in Argentina: Lorlatinib VS Alectinib

Abstract

Authors

E Seyahian I Perez G Correa Zeballos M Mac Mullen

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×